| Not Yet Recruiting | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers NCT07524530 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) NCT07519811 | Technical University of Munich | N/A |
| Not Yet Recruiting | Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy NCT07234630 | University Hospital, Strasbourg, France | — |
| Recruiting | Influenza Vaccination Strategy for Patients With Hematologic Malignancy NCT07485855 | Asan Medical Center | Phase 3 |
| Recruiting | Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide- NCT07162038 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash NCT07179094 | Şule Güzle | N/A |
| Completed | Laser vs Ozone Therapy for Oral Mucositis in Cancer Patients NCT07069153 | University of Pavia | N/A |
| Recruiting | Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion NCT06685848 | Hemanext | N/A |
| Recruiting | A Multi-center Investigation of Family Health. NCT06433349 | Odense University Hospital | — |
| Recruiting | Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patie NCT06422533 | Instituto Nacional de Cancerologia de Mexico | N/A |
| Unknown | The ACC Preclinical Research Platform for Precision Oncology NCT06339541 | Fondazione del Piemonte per l'Oncologia | — |
| Completed | Evaluation of ClearLLab LS Screening Panel NCT05819762 | Beckman Coulter, Inc. | — |
| Completed | RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL NCT05902845 | Xiaoyu Zhu | EARLY_Phase 1 |
| Completed | Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiat NCT05895994 | MEI HENG | EARLY_Phase 1 |
| Completed | Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster O NCT05907603 | Kai Lin Xu，MD | EARLY_Phase 1 |
| Completed | CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL NCT05716113 | He Huang | EARLY_Phase 1 |
| Unknown | Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignanci NCT05672420 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Completed | Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital NCT05549232 | Hemanext | — |
| Completed | CD155 Expression in Acute Myeloid Leukemia NCT06369662 | Assiut University | — |
| Recruiting | Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malign NCT05327023 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Usi NCT05256537 | Ronald Paquette | Phase 2 |
| Completed | Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey NCT05061095 | UNC Lineberger Comprehensive Cancer Center | — |
| Recruiting | Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) NCT04448184 | Ottawa Hospital Research Institute | Phase 3 |
| Unknown | Mindfulness-based Virtual Reality Intervention NCT05602051 | Nanjing University of Traditional Chinese Medicine | N/A |
| Not Yet Recruiting | Immunological Profile for Patients Treated With CAR-T Cells NCT05054231 | Institut Paoli-Calmettes | N/A |
| Recruiting | Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing NCT04959175 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cel NCT04275154 | University of Nebraska | — |
| Completed | Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden NCT04760184 | Uppsala University | — |
| Unknown | Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals NCT04871165 | Vilnius University | — |
| Recruiting | Prospective Validation of the OHI Index NCT05882175 | Meir Medical Center | — |
| Recruiting | Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation NCT04691284 | National Cancer Institute, Slovakia | N/A |
| Unknown | Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant NCT04323605 | University Hospital, Toulouse | N/A |
| Terminated | Natural Killer Cell (CYNK-001) Infusions in Adults with AML NCT04310592 | Celularity Incorporated | Phase 1 |
| Completed | Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation NCT03680092 | Dimitrios Tzachanis, MD PhD | Phase 2 |
| Active Not Recruiting | Optimizing PTCy Dose and Timing NCT03983850 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA NCT04264767 | Nucleix Ltd. | — |
| Unknown | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma NCT03908138 | Shandong Provincial Hospital | Phase 4 |
| Recruiting | Bleeding In Thrombocytopenia Explained NCT03505086 | Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research | — |
| Terminated | Early Palliative Care and Hematological Cancer Patients NCT03743480 | Azienda USL Reggio Emilia - IRCCS | N/A |
| Suspended | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malig NCT03722186 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Terminated | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System NCT03648372 | Takeda | Phase 1 / Phase 2 |
| Completed | Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) NCT03483194 | Weprom | Phase 2 / Phase 3 |
| Completed | Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT NCT03575767 | Affiliated Hospital to Academy of Military Medical Sciences | — |
| Unknown | Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia NCT03288441 | Maastricht University Medical Center | — |
| Completed | The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients NCT04303091 | Dr. Nicole Culos-Reed | N/A |
| Completed | Therapeutic Education in Physical Activity (ETAF) NCT03403075 | Azienda USL Reggio Emilia - IRCCS | N/A |
| Unknown | Prophylactic Early PN in HPT/BMT NCT03083327 | University of Sydney | N/A |
| Terminated | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physicia NCT02900248 | CureOne | — |
| Unknown | Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT NCT03320915 | Seoul National University Hospital | Phase 2 |
| Recruiting | Mind-body Medicine for Patients With Malignant Hematological Diseases NCT03735992 | Universität Duisburg-Essen | N/A |
| Recruiting | Cognitive Training Intervention and Attitudes Towards Genetics NCT03094026 | University of Alabama at Birmingham | N/A |
| Completed | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms NCT03219268 | MacroGenics | Phase 1 |
| Completed | Genomic Testing and Resulting Medical Decisions NCT03301493 | Arbeitsgemeinschaft medikamentoese Tumortherapie | — |
| Completed | Shared Health Information System for Febrile Neutropenia NCT03087227 | Marie-Helene METZGER | N/A |
| Unknown | Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients NCT02944045 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | Pre-myeloid Cancer and Bone Marrow Failure Clinic Study NCT02958462 | Mayo Clinic | N/A |
| Terminated | A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For E NCT02895529 | Xian-Janssen Pharmaceutical Ltd. | Phase 4 |
| Completed | Impact of Pulmonary Follow-up After Stem Cell Graft NCT03349372 | Hospices Civils de Lyon | — |
| Completed | Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study NCT02650791 | Ottawa Hospital Research Institute | Phase 3 |
| Active Not Recruiting | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant NCT02477878 | Bellicum Pharmaceuticals | Phase 1 |
| Completed | Phase I Trial of BAY1251152 for Advanced Blood Cancers NCT02745743 | Bayer | Phase 1 |
| Recruiting | UWCCC Molecular Tumor Board Registry NCT03023202 | University of Wisconsin, Madison | — |
| Completed | Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From a NCT02623309 | Institut Paoli-Calmettes | Phase 3 |
| Completed | Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chem NCT02635984 | Augusta University | Phase 3 |
| Completed | TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia NCT03136445 | NHS Blood and Transplant | Phase 3 |
| Completed | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers NCT02367196 | Celgene | Phase 1 |
| Completed | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of NCT02329847 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Completed | Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Trans NCT01790568 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (H NCT02193880 | Ayman Saad | N/A |
| Completed | Comprehensive Frailty Assessment NCT02033928 | Ohio State University Comprehensive Cancer Center | — |
| Completed | A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Mali NCT02061761 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units NCT02504047 | University of Calgary | N/A |
| Completed | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Deh NCT01915498 | Celgene | Phase 1 / Phase 2 |
| Completed | Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a No NCT01802879 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy NCT01869218 | University of Colorado, Denver | — |
| Completed | Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant NCT01244906 | Northside Hospital, Inc. | Phase 2 |
| Completed | Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation NCT01275534 | University Hospital, Basel, Switzerland | — |
| Completed | National Marrow Donor Program Long-Term Donor Follow-Up NCT01362179 | Center for International Blood and Marrow Transplant Research | — |
| Unknown | Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentica NCT01374841 | European Institute of Oncology | Phase 2 |
| Unknown | Intra-bone Cord Blood Transplantation NCT01332006 | Università degli Studi di Brescia | Phase 2 |
| Terminated | Trial of Pimasertib in Hematological Malignancies NCT00957580 | EMD Serono | Phase 2 |
| Completed | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States NCT00997386 | University of Arizona | Phase 2 |
| Completed | Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignanci NCT00914849 | Washington University School of Medicine | Phase 2 |
| Completed | The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants NCT01021683 | Janssen Korea, Ltd., Korea | — |
| Completed | Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer NCT00900614 | Aprea Therapeutics | Phase 1 |
| Unknown | Biomarker Research for Personalized Medicine NCT01488591 | Inje University | — |
| Completed | A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. NCT00623870 | Hoffmann-La Roche | Phase 1 |
| Completed | Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors NCT00618969 | University of Arizona | Phase 2 |
| Completed | Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies NCT00595686 | Esanex Inc. | Phase 1 |
| Completed | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and E NCT00526045 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Allogeneic Hematopoietic Stem Cell Transplantation NCT00750126 | University Hospital, Clermont-Ferrand | Phase 2 |
| Completed | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers NCT00421213 | Alaunos Therapeutics | Phase 2 |
| Completed | Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic NCT00389428 | Jazz Pharmaceuticals | Phase 1 |
| Terminated | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation NCT00698685 | University of Arizona | Phase 2 |
| Completed | Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion NCT00987987 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients NCT00473577 | Pharmacyclics LLC. | Phase 1 |
| Recruiting | Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Fam NCT00071045 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to NCT00067730 | Eli Lilly and Company | Phase 4 |
| Completed | Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers NCT00051311 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer NCT00312429 | Duke University | Phase 1 / Phase 2 |
| Completed | Clofarabine in Chronic Lymphocytic Leukemia NCT00028418 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malig NCT00001748 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies NCT00038376 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Ma NCT00044759 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |